IMRX

IMRX

USD

Immuneering Corporation Class A Common Stock

$1.450-0.020 (-1.361%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$1.470

Максимум

$1.490

Минимум

$1.430

Объем

0.01M

Фундаментальные показатели компании

Рыночная капитализация

52.5M

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

0.20M

Биржа

NGM

Валюта

USD

52-недельный диапазон

Минимум $1Текущая $1.450Максимум $3.83

Связанные новости

Analyst Upgrades

Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target

Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.

Просмотреть больше
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
GlobeNewswire

Immuneering Corporation Announces Grant of Inducement Award

CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for

Просмотреть больше
Immuneering Corporation Announces Grant of Inducement Award
Analyst Upgrades

Needham Reiterates Buy on Immuneering, Maintains $12 Price Target

Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.

Просмотреть больше
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical

Просмотреть больше
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of

Просмотреть больше
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.